Compounded Sema Injectable denied for failing step therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for compounded sema injectable are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied Under Step Therapy — and Why You Can Appeal

UnitedHealthcare's step-therapy ("fail-first") protocol for compounded semaglutide injectable requires evidence that you have tried — and had an inadequate response to, or cannot tolerate — one or more earlier-line treatments before UHC will approve coverage for the compounded form. When the prior-authorization submission lacks documentation of those prior steps, UHC denies coverage and directs the prescriber to start with a preferred alternative first.

Step-therapy denials are among the most commonly overturned on appeal. In many cases the prior-step treatments have already been tried and the documentation simply was not included in the original PA request. In others, there is a clinical reason why the required prior step is medically inappropriate for this patient — which is a recognized basis for a step-therapy exception.

## Your Federal Appeal Rights

Under ACA §2719 you have the right to independent external review after exhausting UHC's internal process. Under ERISA §503 (employer-sponsored plans) you are entitled to a full-and-fair review with access to every criterion and policy document UHC applied. The external-review window is generally open for approximately four months after a final internal denial. If your health would be seriously harmed by delay, request an expedited 72-hour review.

## The Concrete Appeal Process

1. Obtain UHC's written step-therapy protocol for compounded GLP-1 injectables — identify precisely which step(s) UHC claims have not been completed. 2. Gather your complete medication history and chart notes to determine whether those steps were already taken. 3. File a Level 1 internal appeal with a complete clinical package (see below). 4. If denied, escalate to Level 2 internal appeal and then to external IRO review, which is binding on UHC.

## Documentation to Gather

• Diagnosis confirmation — chart notes, diagnostic codes, and clinical assessments for the underlying condition.
• Prior-treatment history with dates and outcomes — this is the central document for a step-therapy appeal. For each step required by UHC, provide: the agent used, the start and stop dates, the clinical outcome, and the reason the treatment was stopped or deemed insufficient (lack of efficacy, adverse effects, contraindication, or other clinical reason). Pharmacy dispensing records and chart notes are both useful here.
• Clinical severity documentation — chart entries showing the degree of illness and functional impact, particularly if delay in effective treatment poses a health risk.
• Prescriber medical-necessity letter — should address each required step explicitly: either confirming it was completed (with reference to the chart evidence) or explaining the clinical reason it cannot be completed for this specific patient. A step-therapy exception request based on clinical contraindication is a recognized and frequently granted pathway.
• Applicable guideline reference — the prescriber may cite the relevant clinical practice guideline by organization name (e.g., the applicable Obesity Medicine Association or Endocrine Society guidance) to support that the prescribed therapy is consistent with the standard of care for this patient's presentation.

## Criteria-Mapping Structure

Build a step-by-step table using UHC's exact protocol requirements:

| Step Required by UHC | Evidence of Completion or Clinical Exception Basis | |---|---| | [List each required prior agent or treatment class exactly as UHC states it] | [Date tried, duration, outcome — or specific clinical reason this step is not appropriate for this patient] |

A step-therapy appeal that addresses each required step individually — with specific chart evidence or a documented clinical exception basis for each — is far stronger than a general letter asserting that the prescribed treatment is appropriate. Match UHC's own protocol criteria point by point and the reviewer cannot deny on a technicality.